Keyword: Arrakis Therapeutics
Gilman to be full-time CEO of Arrakis, while Wotton takes over Obsidian; ex-GSK immunology chief to lead Kintai Therapeutics; and Insys swaps CEOs.
Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company advances four RNA-targeting drugs.
This year’s class of Fierce 15 landed during a banner year for venture capital investment in biotech. We asked them if they thought the trend would continue or if the bubble would burst.
Mining the RNA world for new medicines.
All of our Fierce 15 winners care deeply about biomedical science and understand the unique pressure to translate every penny they've raised into something truly innovative for patients. And it seems this passion is infectious when it comes to luring investors.